Biomea Fusion Analyst Ratings
Biomea Fusion Initiated at Overweight by Capital One
Capital One Initiates Coverage On Biomea Fusion With Overweight Rating, Announces Price Target of $25
Capital One Financial Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $25
Biomea Fusion Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on Biomea Fusion, Lowers Price Target to $22
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $22
Truist Financial Maintains Biomea Fusion(BMEA.US) With Hold Rating
Biomea Fusion Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Biomea Fusion Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $15 Price Target
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $21
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $15
Buy Rating Affirmed for Biomea Fusion Amid Anticipated Clinical Advancements and Solid Financial Footing
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA), Stryker (SYK) and Teladoc (TDOC)
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $15 Price Target
Biomea Fusion Analyst Ratings
Truist Cuts Biomea Fusion to Hold, Cites Clinical Hold Uncertainty
Biomea Fusion Analyst Ratings
Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week